Drugs Containing Excipient (Inactive Ingredient) SUCROSE

Branded drugs containing SUCROSE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	CYMBALTA	duloxetine hydrochloride	0002-3235	SUCROSE
Merck Sharp & Dohme LLC	EMEND	aprepitant	0006-0461	SUCROSE
Merck Sharp & Dohme Corp	FOSAMAX PLUS D	alendronate sodium and cholecalciferol	0006-0710	SUCROSE

Generic drugs containing SUCROSE excipient

Company	Ingredient	NDC	Excipient
Eli Lilly and Company	ixekizumab	0002-1445	SUCROSE
Eli Lilly and Company	duloxetine hydrochloride	0002-3235	SUCROSE
Eli Lilly and Company	lebrikizumab-lbkz	0002-7772	SUCROSE

Sucrose Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: September 8, 2026

Sucrose is a low-cost, globally available pharmaceutical excipient used in oral solid doses, oral liquids, biologic formulations, vaccines, lyophilized products, and parenteral stabilizers. Its molecule has no meaningful remaining composition-of-matter patent protection. Commercial value resides in pharmaceutical-grade quality systems, impurity control, particle engineering, low-endotoxin production, documentation, and supply reliability.

Demand should expand at a moderate rate through the decade. Growth is tied to biologics, vaccines, biosimilars, lyophilized injectables, and pediatric formulations. Revenue growth for pharmaceutical-grade sucrose is likely to exceed volume growth when manufacturers shift toward higher-purity, low-endotoxin, sterile, or tightly controlled grades. The main constraints are sugar-crop volatility, competition from trehalose and polyols, and the limited pricing power of a commodity-derived excipient.

What is the pharmaceutical excipient sucrose market?

Sucrose is a disaccharide composed of glucose and fructose. In drug products, it functions as a filler, sweetener, bulking agent, tonicity modifier, stabilizer, cryoprotectant, and lyoprotectant.

Application	Primary function	Main dosage forms
Oral solid dosage	Diluent, binder support, taste masking	Tablets, lozenges, powders
Oral liquids	Sweetener, viscosity and palatability aid	Syrups, solutions, suspensions
Biologics	Stabilizer against aggregation and denaturation	Proteins, antibodies, vaccines
Lyophilized products	Bulking agent and glass-forming stabilizer	Vials and biologic powders
Parenterals	Stabilizer and tonicity modifier	Injectable biologics
Coated products	Sweetening and coating excipient	Dragees, coated tablets
Diagnostics	Stabilizer and bulking component	Reagents and kits

Sucrose is listed in major pharmacopeial systems, including the United States Pharmacopeia-National Formulary, European Pharmacopoeia, and Japanese Pharmacopoeia. The FDA Inactive Ingredient Database contains sucrose entries across multiple routes and dosage forms, supporting its established regulatory use in approved products (FDA, 2024a; USP, 2024).

How large is the pharmaceutical-grade sucrose market?

No single public, audited market series isolates pharmaceutical-grade sucrose from food, nutrition, biotechnology, and laboratory applications. Commercial market estimates usually group sucrose with sugar-based excipients or broader pharmaceutical excipients. This makes precise market-share and revenue calculations unreliable.

The market has three distinct layers:

1. Commodity sucrose: Produced at very large scale from sugarcane and sugar beet. Pharmaceutical demand is a small fraction of total global sugar consumption.
2. Pharmaceutical-grade sucrose: Subject to pharmacopeial testing, controlled manufacturing, traceability, and change-control requirements.
3. Specialized biologic and parenteral grades: Require tighter microbial, endotoxin, particulate, moisture, and impurity specifications. Sterile or low-endotoxin grades command the highest prices.

The value pool is therefore not determined by sugar tonnage alone. A small volume of high-specification sucrose used in biologic manufacturing can generate more supplier revenue than substantially larger volumes of standard oral-grade material.

What drives sucrose excipient demand?

The principal growth drivers are:

• Expansion of monoclonal antibody and recombinant-protein manufacturing.
• Growth in vaccines and temperature-sensitive injectable products.
• Increasing use of lyophilization for biologics and specialty injectables.
• Expansion of biosimilar production.
• Continued demand for pediatric and geriatric oral formulations.
• Use in cell and gene therapy process development, although the volumes remain smaller than for antibodies and vaccines.
• Preference for established, compendial excipients during regulatory submissions.

Biologic manufacturers often select sucrose because it has a long regulatory history and can stabilize proteins during freezing, drying, and storage. It is not universally interchangeable with trehalose or other stabilizers. The selection depends on protein chemistry, concentration, container closure, reconstitution behavior, osmolality, and the final storage profile.

What are the main pharmaceutical applications of sucrose?

Biologic stabilization

Sucrose protects proteins through preferential exclusion and formation of an amorphous glass during drying. In lyophilized products, it can reduce aggregation and structural damage caused by freezing and dehydration. In liquid formulations, it may improve stability but can increase viscosity and affect osmolality.

Sucrose is common in formulations involving:

• Monoclonal antibodies
• Enzyme replacement therapies
• Recombinant proteins
• Vaccines
• Peptide and protein injectables
• Freeze-dried diagnostic reagents

The commercial opportunity is strongest where product value is high and formulation failure has material manufacturing consequences.

Oral solid dosage

Sucrose is used as a diluent, sweetener, and coating component. It is particularly relevant to lozenges, chewable products, granules, powders, and sugar-coated tablets.

Its use is constrained by:

• Dental-caries concerns
• High caloric content
• Hygroscopicity and moisture sensitivity
• Reduced suitability for diabetes-focused products
• Competition from mannitol, sorbitol, xylitol, lactose, and microcrystalline cellulose

Oral liquids

Sucrose is widely used in syrups and pediatric medicines because it improves taste and supports patient acceptance. Manufacturers must control microbial growth, preservative compatibility, crystallization, viscosity, and density.

Sugar-free formulations increasingly use polyols or high-intensity sweeteners. This limits growth in some consumer-facing and chronic-use products.

What is the FDA regulatory status of pharmaceutical sucrose?

Sucrose is an established inactive ingredient rather than a new excipient requiring a novel regulatory pathway in every use. Its acceptability depends on the route, dose, concentration, product design, manufacturing process, and supporting safety data.

The FDA evaluates sucrose through its use in specific approved drug products and the Inactive Ingredient Database. The database is not a blanket authorization for every concentration or route. A formulation outside established precedent may require additional justification in an abbreviated or full application.

For biologics, sucrose is evaluated as part of the product's chemistry, manufacturing, and controls package. Sponsors must demonstrate that the excipient does not compromise potency, purity, stability, sterility, or container compatibility.

Relevant regulatory controls include:

• USP/NF identity, assay, impurity, and microbial requirements.
• European Pharmacopoeia compliance for European submissions.
• GMP controls under the supplier's quality system.
• Change notification and comparability requirements.
• Control of bioburden and endotoxin for parenteral applications.
• Animal-origin and allergen documentation where required by the sponsor.
• Elemental impurity and extractables assessments where relevant.

What patents protect pharmaceutical sucrose?

No active composition-of-matter patent meaningfully protects sucrose as a pharmaceutical excipient. Sucrose is an old, naturally occurring compound with extensive prior use.

IP category	Protection status	Commercial relevance
Sucrose molecule	No meaningful active exclusivity	None
General pharmaceutical use	Broad prior art; generally unprotected	Low
Specific biologic formulation	May be protected by product patents	High for the drug sponsor
Lyophilization cycle	May be protected by process patents	Moderate to high
Sterile or low-endotoxin manufacturing	Process know-how and possible patents	Supplier-specific
Particle engineering or co-processing	Possible patents or trade secrets	Moderate
Brand and grade names	Trademarks	Supplier differentiation
Supplier specifications	Confidential know-how and quality systems	High operational value

A patent covering a biologic formulation that contains sucrose protects the drug product or formulation combination, not sucrose as a standalone chemical. Those patents can influence excipient demand because a generic or biosimilar sponsor may need to design around the formulation or license the relevant rights.

Are there Paragraph IV challenges involving sucrose?

Paragraph IV litigation is generally not relevant to sucrose itself. Paragraph IV certifications address patents listed for an approved drug in the FDA Orange Book. Sucrose is an inactive ingredient and is not typically the listed subject of an Orange Book exclusivity dispute.

Paragraph IV risk may arise indirectly when sucrose is included in a patented drug formulation. The dispute concerns the finished drug's formulation, method of use, or manufacturing process. It does not create standalone exclusivity for sucrose.

Are there biosimilar risks for sucrose?

Biosimilar adoption is a net volume opportunity for sucrose suppliers but can create price pressure. Biosimilar developers commonly use established stabilizers to reduce formulation and regulatory risk. That supports demand for compendial sucrose in biologics manufacturing.

The risk is substitution. A biosimilar sponsor may select trehalose, histidine-based systems, arginine, polysorbates, or other stabilizers to avoid patent claims, improve stability, or differentiate the product. The resulting effect on sucrose demand depends on formulation-specific compatibility rather than on the biosimilar pathway alone.

When does sucrose lose exclusivity?

Sucrose does not have a conventional pharmaceutical exclusivity date. It is a longstanding generic chemical and compendial excipient.

The relevant exclusivity timelines apply to drug products containing sucrose:

Exclusivity category	Relevance to sucrose
Sucrose composition patent	No material active exclusivity
Drug formulation patent	May delay generic or biosimilar entry
Method-of-use patent	May restrict a specific therapeutic use
Manufacturing patent	May affect a particular process
FDA new chemical entity exclusivity	Not applicable to sucrose
Orphan-drug exclusivity	Applies to the approved drug, not sucrose
Biologic reference-product exclusivity	Applies to the biologic, not sucrose
Orange Book listing	Applies to eligible approved drug patents

The commercial lifecycle of sucrose is therefore driven by product launches, formulation transfers, supplier qualification, and manufacturing demand rather than patent expiry.

How strong is the sucrose patent estate?

The standalone patent estate is weak because the core molecule and most broad uses are old. The defensible commercial estate is concentrated in manufacturing capability and customer qualification.

Stronger protection areas

• Proprietary low-endotoxin purification.
• Sterile filling or sterile-packaging processes.
• Narrow particle-size distributions.
• Controlled crystallinity and amorphous content.
• Co-processed excipient systems.
• Specialized grades for lyophilized biologics.
• Validated supply chains and regulatory files.
• Confidential process parameters and analytical methods.

Weaker protection areas

• Generic sucrose use as a sweetener.
• Generic use as a tablet filler.
• Broad claims covering sucrose in protein formulations.
• Standard compendial testing.
• Commodity production methods.

Trade secrets, customer audits, technical support, and regulatory change-control performance are more important than patents in ordinary sucrose supply.

What companies supply pharmaceutical-grade sucrose?

The supply base includes sugar producers, pharmaceutical raw-material manufacturers, specialty excipient suppliers, and global distributors. Supplier qualification is usually grade-specific rather than company-wide.

Relevant supplier categories include:

• Large sugar producers with pharmaceutical-grade operations.
• Specialty carbohydrate manufacturers.
• Excipient companies that offer compendial sucrose grades.
• Catalog suppliers serving laboratory and small-scale manufacturing markets.
• Regional distributors that provide import, storage, and regulatory documentation.

Supplier selection typically evaluates:

• USP/NF and Ph. Eur. compliance.
• Manufacturing-site inspection history.
• DMF or equivalent regulatory support.
• Batch-to-batch impurity consistency.
• Microbial and endotoxin controls.
• Supply continuity and dual sourcing.
• Change-notification procedures.
• Packaging and storage controls.
• Country-of-origin and traceability records.

The commercial advantage of a supplier is strongest when switching requires extensive formulation bridging, process validation, stability work, or regulatory notification.

What is the financial trajectory for pharmaceutical sucrose?

Revenue growth should be moderate rather than explosive. Volume growth will likely track pharmaceutical manufacturing growth, with biologics and vaccines growing faster than conventional oral solids. Pricing will depend on grade and supply conditions.

Financial driver	Expected effect
Biologic manufacturing growth	Positive
Biosimilar expansion	Positive volume effect; mixed price effect
Vaccine demand	Positive but episodic
Sugar-crop shortages	Higher input costs and margin pressure
Energy and freight costs	Higher delivered cost
Supplier qualification barriers	Supports premium pricing
Generic oral-dose competition	Limits price increases
Trehalose substitution	Negative in selected formulations
Sterile and low-endotoxin grades	Positive mix effect
Long-term supply contracts	Reduces spot-price volatility

A reasonable market model separates revenue into volume and mix:

• Volume growth: Driven by the number of drug products and biologic batches using sucrose.
• Mix growth: Driven by movement toward specialized, validated, low-endotoxin, or sterile grades.
• Price growth: Constrained by commodity sugar economics and alternative excipients.

The strongest margin opportunity is not standard oral-grade sucrose. It is higher-specification material sold into regulated biologic and parenteral manufacturing, where the cost of an excipient failure is large relative to the material price.

How does sucrose compare with trehalose and mannitol?

Attribute	Sucrose	Trehalose	Mannitol
Primary role	Stabilizer, filler, sweetener	Biologic stabilizer	Bulking agent, tonicity modifier
Relative cost	Generally low	Usually higher	Moderate
Biologic use	Established	Strong and expanding	More limited as primary stabilizer
Lyophilization	Widely used	Widely used	Strong bulking performance
Oral sweetness	High	Moderate	Low
Hygroscopicity	Relevant	Relevant but formulation-dependent	Relatively low
Patent risk	Low for molecule	Low for molecule	Low for molecule
Supply economics	Linked to sugar markets	Specialty carbohydrate economics	Industrial and pharmaceutical production
Substitution risk	Moderate	Moderate	High in some oral and lyophilized products

Sucrose is most competitive when a sponsor values regulatory familiarity, low cost, and established protein-stabilization performance. Trehalose can compete in biologics where stability or formulation design favors it. Mannitol is more attractive where low hygroscopicity, crystalline bulking, or a less sweet excipient is required.

What manufacturing and IP barriers affect sucrose supply?

The principal barriers are operational rather than legal.

A new supplier must demonstrate:

1. Reliable raw-material sourcing.
2. Consistent purification and crystallization.
3. Control of color, ash, reducing sugars, heavy metals, and residual contaminants.
4. Microbial and endotoxin management.
5. Validated analytical methods.
6. GMP documentation and audit readiness.
7. Packaging that prevents moisture uptake and contamination.
8. Regulatory support for customer submissions.
9. Long-term change-control discipline.

Pharmaceutical customers often dual-source sucrose only after extensive comparability work. A supplier with a lower nominal price may still lose on total cost if the customer must repeat stability studies, process validation, or regulatory filings.

What licensing deals and litigation affect pharmaceutical sucrose?

There is no major industrywide sucrose licensing structure comparable with patented active pharmaceutical ingredients. Supply agreements, quality agreements, technology transfers, and private-label arrangements are more common than public patent licenses.

Public litigation is generally concentrated in the finished drug or biologic product. Relevant disputes may involve:

• Formulations containing sucrose.
• Lyophilization processes.
• Protein stabilization claims.
• Biosimilar manufacturing methods.
• Supplier quality failures.
• Contract-manufacturing obligations.

A patent search focused only on "sucrose" will overstate risk by capturing patents for drug products that happen to include the excipient. Freedom-to-operate analysis must separate standalone sucrose claims from claims covering a specific active ingredient, concentration range, formulation, or manufacturing step.

What is the geographic outlook for sucrose excipients?

North America and Europe remain high-value markets because of biologic manufacturing, regulatory scrutiny, and demand for documented pharmaceutical grades. Asia-Pacific is the fastest-growing demand region in volume terms, supported by generic drugs, biosimilars, vaccines, contract development, and expanding injectable capacity.

Region	Market characteristics
United States	High biologic demand, stringent supplier qualification, Orange Book and BLA-driven formulation work
Europe	Strong pharmacopeial compliance, biologics and vaccine production, emphasis on GMP supply chains
China	Expanding API, biologic, and vaccine manufacturing; rising domestic excipient capability
India	Large generic and biosimilar base; price-sensitive procurement with growing quality requirements
Japan	Mature pharmaceutical market with high quality and documentation standards
Latin America	Oral dosage and syrup demand; greater exposure to imported specialty grades

Geographic risk is determined by both sugar availability and pharmaceutical manufacturing concentration. A region can have abundant commodity sugar but limited capacity for compliant pharmaceutical-grade purification and documentation.

Key Takeaways

• Sucrose is an established, compendial pharmaceutical excipient with broad use in oral drugs, biologics, vaccines, and lyophilized products.
• It has no meaningful standalone molecule patent estate or conventional exclusivity date.
• The strongest demand growth is linked to biologics, biosimilars, vaccines, and injectable manufacturing.
• Specialized low-endotoxin and sterile grades offer better pricing and margin potential than standard oral-grade material.
• Sugar-crop prices, energy, freight, and crop policy create input-cost volatility.
• Trehalose and mannitol are the principal technical substitutes in selected formulations.
• Supplier differentiation depends more on quality systems, regulatory documentation, technical support, and supply continuity than on patents.
• Paragraph IV challenges and Orange Book disputes affect finished drugs containing sucrose, not sucrose itself.
• Biosimilar growth should increase aggregate demand while increasing pressure to optimize formulation cost.
• The financial outlook is moderate, with mix-driven upside in biologic and parenteral grades.

FAQs

Is sucrose considered a pharmaceutical excipient?

Yes. Sucrose is an established excipient used as a diluent, sweetener, stabilizer, bulking agent, cryoprotectant, and lyoprotectant.

Is pharmaceutical-grade sucrose different from food-grade sugar?

Yes. Pharmaceutical-grade material is manufactured and documented to meet applicable pharmacopeial, GMP, impurity, microbial, traceability, and change-control requirements. Food-grade status alone does not establish suitability for a drug product.

Can sucrose be used in injectable biologics?

Yes, subject to formulation-specific development and control requirements. Injectable use requires appropriate microbial, endotoxin, particulate, purity, stability, and compatibility assessments.

Does sucrose create patent infringement risk for biosimilars?

Sucrose itself generally does not. Risk may arise from patents covering the reference biologic's formulation, concentration, stabilization system, lyophilization process, or manufacturing method.

Which excipient is the closest substitute for sucrose?

Trehalose is the closest functional substitute for many biologic-stabilization applications. Mannitol is a stronger substitute where the principal requirement is crystalline bulking or moisture control.

References

1. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia (11th ed.). Council of Europe.

2. International Council for Harmonisation. (2000). Q7: Good manufacturing practice guide for active pharmaceutical ingredients. ICH.

3. U.S. Food and Drug Administration. (2024a). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=inactiveingredientdatabase

4. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary (USP 47-NF 42). United States Pharmacopeial Convention.